COVID‐19‐Associated Chemosensory Loss Continues to Decline
Authors:
- Evan R. ReiterEREvan R. Reiter
- N3C ConsortiumNCN3C Consortium
- 26 May 2023
- journal article
- research article
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 169 (5) , 1386-1389
Abstract
Chemosensory losses have long been considered a cardinal symptom of COVID‐19 infection. Recent studies have shown changing symptom profiles with COVID‐19, including decreasing incidence of olfactory losses. We accessed the National COVID Cohort Collaborative database to identify patients with and without smell and taste loss within 2 weeks of COVID‐19 diagnosis. Peak prevalence time intervals for variants were determined from Covariants.org. Using rates of chemosensory loss during the peak time interval for “Untyped” variants as baseline (4/27/2020‐6/18/2020), odds ratios for COVID‐19‐associated smell or taste disturbance fell for each of the Alpha (0.744), Delta (0.637), Omicron K (0.139), Omicron L (0.079), Omicron C (0.061), and Omicron B (0.070) peak intervals. These data suggest that during the recent Omicron waves and potentially moving forward, the presence or absence of smell and taste disturbances may no longer have predictive value in the diagnosis of COVID‐19 infection.Keywords
This publication has 8 references indexed in Scilit:
- Decreasing Incidence of Chemosensory Changes by COVID‐19 VariantOtolaryngology–Head and Neck Surgery, 2023
- COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USAEmerging Infectious Diseases, 2023
- Comparison of Clinical Presentation and Vaccine Effectiveness Among Omicron and Non-omicron SARS Coronavirus-2 PatientsCureus, 2022
- Comparative symptomatology of infection with SARS-CoV-2 variants Omicron (B.1.1.529) and Delta (B.1.617.2) from routine contact tracing data in EnglandEpidemiology and Infection, 2022
- Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID StudyThe Lancet, 2022
- Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics2021
- Association of chemosensory dysfunction and COVID‐19 in patients presenting with influenza‐like symptomsInternational Forum of Allergy & Rhinology, 2020
- The Prevalence of Olfactory and Gustatory Dysfunction in COVID‐19 Patients: A Systematic Review and Meta‐analysisOtolaryngology–Head and Neck Surgery, 2020